Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II study of axitinib as the second-line on the treatment of advanced
hepatocellular carcinoma (HCC).
The purpose of this study is a proof-of-concept study to see if axitinib has any anti-tumor
effect in HCC. The primary endpoint is disease stabilization that lasts for at least 8 weeks
without progression of tumor-related symptoms.
Phase:
Phase 2
Details
Lead Sponsor:
National Taiwan University Hospital
Collaborators:
Taipei Veterans General Hospital, Taiwan Tri-Service General Hospital